Meeting
2016 ASCO Annual Meeting
Phase I results of mitoxantrone in combination with clofarabine in children, adolescents and young adults with refractory/relapsed acute leukemia.
Authors
Jessica Hochberg
New York Medical College, Valhalla, NY
Jessica Hochberg , Javier E. Oesterheld , Olga Militano , Liana Klejmont , Lauren Harrison , Berkley Nickerson , Mitchell S. Cairo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Leukemia/Lymphoma
Clinical Trial Registration Number
NCT01843672
Citation
J Clin Oncol 34, 2016 (suppl; abstr 10533)
DOI
10.1200/JCO.2016.34.15_suppl.10533
Abstract #
10533
Poster Bd #
224
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Phase II results of mitoxantrone in combination with clofarabine in children with relapsed/refractory acute leukemia.
First Author: Jessica Hochberg
Poster
2019 ASCO Annual Meeting
Vincristine, irinotecan, and temozolomide as a salvage regimen for relapsed or refractory sarcoma in children and young adults.
First Author: Byung-Kiu Park
Poster
2016 ASCO Annual Meeting
A phase I/pilot study of CPX-351 for children, adolescents and young adults with recurrent or refractory hematologic malignancies.
First Author: Michael Absalon
Poster
2015 ASCO Annual Meeting
Phase 1 trial of brentuximab vedotin in combination with gemcitabine for pediatric and young adult patients with relapsed or refractory Hodgkin lymphoma, a Children’s Oncology Group report.
First Author: Peter D. Cole